Published in J Proteome Res on April 17, 2013
Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapies. Curr Med Chem (2014) 0.94
Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations. Biomaterials (2014) 0.90
Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment. J Control Release (2015) 0.83
Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases. Nanomedicine (2015) 0.82
Pharmacokinetics, biodistribution, and toxicity of folic acid-coated antiretroviral nanoformulations. Antimicrob Agents Chemother (2014) 0.80
Cellular Responses and Tissue Depots for Nanoformulated Antiretroviral Therapy. PLoS One (2015) 0.76
Exploring the full spectrum of macrophage activation. Nat Rev Immunol (2008) 26.08
Normalization of cDNA microarray data. Methods (2003) 18.69
Andromeda: a peptide search engine integrated into the MaxQuant environment. J Proteome Res (2011) 14.82
Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med (1988) 9.21
The many faces of macrophage activation. J Leukoc Biol (2003) 8.95
Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res (2009) 7.83
HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med (1995) 5.22
Human macrophage activation programs induced by bacterial pathogens. Proc Natl Acad Sci U S A (2002) 5.18
Ultrastructural study of the behavior of macrophages toward parasitic mycobacteria. Infect Immun (1972) 5.12
Structure and functional expression of a human interleukin-8 receptor. Science (1991) 4.74
Cloning of complementary DNA encoding a functional human interleukin-8 receptor. Science (1991) 3.85
Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J Infect Dis (1992) 3.27
Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol (2006) 3.13
Macrophage receptors for Mycobacterium tuberculosis. Infect Immun (1998) 2.42
Cellular reservoirs of HIV-1 and their role in viral persistence. Curr HIV Res (2008) 2.40
Global analysis of cellular protein translation by pulsed SILAC. Proteomics (2009) 2.15
Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood (2006) 2.13
Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet (2001) 2.01
Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J Immunol (2009) 1.85
The functional significance behind expressing two IL-8 receptor types on PMN. J Leukoc Biol (2009) 1.81
Human immunodeficiency virus (HIV) nef-specific cytotoxic T lymphocytes in noninfected heterosexual contact of HIV-infected patients. J Clin Invest (1994) 1.75
NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery. Nanomedicine (Lond) (2009) 1.72
NanoART, neuroAIDS and CNS drug delivery. Nanomedicine (Lond) (2009) 1.55
Macrophage endocytic trafficking of antiretroviral nanoparticles. Nanomedicine (Lond) (2011) 1.52
Interleukin-8. Crit Care Med (2005) 1.46
Cell biology of HIV-1 infection of macrophages. Annu Rev Microbiol (2008) 1.43
Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics. J Neuroimmune Pharmacol (2010) 1.42
Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. Virology (2006) 1.41
Interaction of Leishmania with a macrophage cell line. Correlation between intracellular killing and the generation of oxygen intermediates. J Exp Med (1981) 1.34
Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice. AIDS (2012) 1.32
Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. J Control Release (2010) 1.28
Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice. J Infect Dis (2012) 1.23
S100A8/9 induces cell death via a novel, RAGE-independent pathway that involves selective release of Smac/DIABLO and Omi/HtrA2. Biochim Biophys Acta (2007) 1.19
Appearance-related side effects of HIV-1 treatment. AIDS Patient Care STDS (2006) 1.12
Mechanisms and consequences of persistence of intracellular pathogens: leishmaniasis as an example. Cell Microbiol (2008) 1.12
Comparative manufacture and cell-based delivery of antiretroviral nanoformulations. Int J Nanomedicine (2011) 1.11
Antigen-specific T-cell-mediated immunity after HIV-1 infection: implications for vaccine control of HIV development. Expert Rev Vaccines (2006) 1.10
Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells. Int J Nanomedicine (2012) 1.08
Autophagy, an immunologic magic bullet: Mycobacterium tuberculosis phagosome maturation block and how to bypass it. Future Microbiol (2008) 1.05
Expression of both types of human interleukin-8 receptors on mature neutrophils, monocytes, and natural killer cells. J Leukoc Biol (1995) 1.05
HIV-1 infected monocyte-derived macrophages affect the human brain microvascular endothelial cell proteome: new insights into blood-brain barrier dysfunction for HIV-1-associated dementia. J Neuroimmunol (2007) 1.05
An insertion mutant in DQA1*0501 restores susceptibility to HLA-DM: implications for disease associations. J Immunol (2011) 1.04
Methods development for blood borne macrophage carriage of nanoformulated antiretroviral drugs. J Vis Exp (2010) 1.03
Antiretroviral compounds: mechanisms underlying failure of HAART to eradicate HIV-1. Curr Med Chem (2005) 1.00
Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097). J Med Virol (2005) 0.96
New insights into determinants of Listeria monocytogenes virulence. Int Rev Cell Mol Biol (2008) 0.94
Pulsed stable isotope labeling of amino acids in cell culture uncovers the dynamic interactions between HIV-1 and the monocyte-derived macrophage. J Proteome Res (2011) 0.88
Antiretroviral therapy in the developing world. J Neurovirol (2005) 0.88
Replication of HIV-1 in vivo and in vitro. Ultrastruct Pathol (2007) 0.87
Adverse effects of antiretroviral drugs on HIV-1-infected and -uninfected human monocyte-derived macrophages. J Acquir Immune Defic Syndr (2006) 0.86
HIV-1 and the central nervous system. Curr Top Microbiol Immunol (2002) 0.85
Immunologic and virologic consequences of temporary antiretroviral treatment interruption in clinical practice. AIDS Res Hum Retroviruses (2002) 0.83
Calgranulin B (S100A9/MRP14): a key molecule in idiopathic pulmonary fibrosis? Inflammation (2011) 0.80
Proteomic biosignatures for monocyte-macrophage differentiation. Cell Immunol (2011) 0.79
A call for transparent reporting to optimize the predictive value of preclinical research. Nature (2012) 14.63
Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature (2012) 13.71
Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol (2012) 3.20
Identification of new fluorescent protein fragments for bimolecular fluorescence complementation analysis under physiological conditions. Biotechniques (2006) 2.99
Predictors of nursing home admission for persons with dementia. Med Care (2009) 2.54
Impaired renal Na(+) retention in the sgk1-knockout mouse. J Clin Invest (2002) 2.47
Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2007) 2.43
Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res (2013) 2.26
Human immunodeficiency virus type 1 pathobiology studied in humanized BALB/c-Rag2-/-gammac-/- mice. J Virol (2006) 2.24
Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood (2006) 2.13
Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Am J Pathol (2007) 2.05
Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2004) 2.01
Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One (2008) 1.99
Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J Immunol (2009) 1.85
Oxidative stress and the pathogenesis of neurodegenerative disorders. Int Rev Neurobiol (2007) 1.84
Expression profile of osteoblast lineage at defined stages of differentiation. J Biol Chem (2005) 1.83
Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease. J Leukoc Biol (2007) 1.80
CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's disease. J Neuroimmune Pharmacol (2012) 1.78
Palmitic acid mediates hypothalamic insulin resistance by altering PKC-theta subcellular localization in rodents. J Clin Invest (2009) 1.77
A pharmacologic inhibitor of the protease Taspase1 effectively inhibits breast and brain tumor growth. Cancer Res (2011) 1.74
HIV-1 gp120 compromises blood-brain barrier integrity and enhances monocyte migration across blood-brain barrier: implication for viral neuropathogenesis. J Cereb Blood Flow Metab (2006) 1.72
NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery. Nanomedicine (Lond) (2009) 1.72
Expression and regulation of intergenic long noncoding RNAs during T cell development and differentiation. Nat Immunol (2013) 1.71
The huge Package for High-dimensional Undirected Graph Estimation in R. J Mach Learn Res (2012) 1.69
The MIT domain of UBPY constitutes a CHMP binding and endosomal localization signal required for efficient epidermal growth factor receptor degradation. J Biol Chem (2007) 1.69
Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice. PLoS One (2008) 1.65
The functional interactome landscape of the human histone deacetylase family. Mol Syst Biol (2013) 1.63
Mononuclear phagocyte immunity and the neuropathogenesis of HIV-1 infection. J Leukoc Biol (2003) 1.62
A functional transsulfuration pathway in the brain links to glutathione homeostasis. J Biol Chem (2006) 1.61
STAT1 signaling modulates HIV-1-induced inflammatory responses and leukocyte transmigration across the blood-brain barrier. Blood (2007) 1.60
Dual molecular imaging for targeting metalloproteinase activity and apoptosis in atherosclerosis: molecular imaging facilitates understanding of pathogenesis. J Nucl Cardiol (2009) 1.60
Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. Clin Cancer Res (2014) 1.57
Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease. J Immunol (2010) 1.57
NanoART, neuroAIDS and CNS drug delivery. Nanomedicine (Lond) (2009) 1.55
Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis. Blood (2005) 1.54
Deubiquitylases from genes to organism. Physiol Rev (2013) 1.54
HIV-1-associated dementia: a basic science and clinical perspective. AIDS Read (2002) 1.54
Nuclear import of histone deacetylase 5 by requisite nuclear localization signal phosphorylation. Mol Cell Proteomics (2010) 1.52
Macrophage endocytic trafficking of antiretroviral nanoparticles. Nanomedicine (Lond) (2011) 1.52
Quantitative diffusion tensor imaging detects dopaminergic neuronal degeneration in a murine model of Parkinson's disease. Neurobiol Dis (2007) 1.52
A nonproton ligand sensor in the acid-sensing ion channel. Neuron (2010) 1.52
Porphyromonas gingivalis and disease-related autoantibodies in individuals at increased risk of rheumatoid arthritis. Arthritis Rheum (2012) 1.52
Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease. Clin Neurosci Res (2006) 1.50
Expression of peroxisome proliferator-activated receptor-gamma in key neuronal subsets regulating glucose metabolism and energy homeostasis. Endocrinology (2008) 1.49
A coat of many colors: neuroimmune crosstalk in human immunodeficiency virus infection. Neuron (2009) 1.48
HIV-1-associated dementia: a metabolic encephalopathy perpetrated by virus-infected and immune-competent mononuclear phagocytes. J Acquir Immune Defic Syndr (2002) 1.46
Overexpression of monocyte chemotactic protein-1/CCL2 in beta-amyloid precursor protein transgenic mice show accelerated diffuse beta-amyloid deposition. Am J Pathol (2005) 1.46
Molecular mechanisms involving sigma receptor-mediated induction of MCP-1: implication for increased monocyte transmigration. Blood (2010) 1.44
MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer. Proc Natl Acad Sci U S A (2012) 1.44
Egr3, a synaptic activity regulated transcription factor that is essential for learning and memory. Mol Cell Neurosci (2007) 1.44
Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics. J Neuroimmune Pharmacol (2010) 1.42
Biochemical and biologic characterization of exosomes and microvesicles as facilitators of HIV-1 infection in macrophages. J Immunol (2012) 1.42
Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. Virology (2006) 1.41
HIV-1-infected and/or immune activated macrophages regulate astrocyte SDF-1 production through IL-1beta. Glia (2006) 1.40
Periodontitis and Porphyromonas gingivalis in patients with rheumatoid arthritis. Arthritis Rheumatol (2014) 1.40
A macrophage-nanozyme delivery system for Parkinson's disease. Bioconjug Chem (2007) 1.38
Nanotechnology: a focus on nanoparticles as a drug delivery system. J Neuroimmune Pharmacol (2006) 1.37
Nitrated alpha-synuclein-activated microglial profiling for Parkinson's disease. J Neurochem (2007) 1.35
Cerebrospinal fluid proteomic profiling of HIV-1-infected patients with cognitive impairment. J Proteome Res (2007) 1.35
Microfluidic device for immunoassays based on surface plasmon resonance imaging. Lab Chip (2008) 1.34
SDF-1/CXCR4 signaling induces pancreatic cancer cell invasion and epithelial-mesenchymal transition in vitro through non-canonical activation of Hedgehog pathway. Cancer Lett (2012) 1.34
Cell-mediated drug delivery. Expert Opin Drug Deliv (2011) 1.33
Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression. Cancer Res (2008) 1.33
Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice. AIDS (2012) 1.32
Black phosphorus-monolayer MoS2 van der Waals heterojunction p-n diode. ACS Nano (2014) 1.32
HIV-1 neuroimmunity in the era of antiretroviral therapy. Neurobiol Dis (2010) 1.32
Facilitated monocyte-macrophage uptake and tissue distribution of superparmagnetic iron-oxide nanoparticles. PLoS One (2009) 1.31
Investigating the human immunodeficiency virus type 1-infected monocyte-derived macrophage secretome. Virology (2007) 1.30
Governance of endocytic trafficking and signaling by reversible ubiquitylation. Dev Cell (2012) 1.29
RNA-binding protein quaking, a critical regulator of colon epithelial differentiation and a suppressor of colon cancer. Gastroenterology (2009) 1.29
Aberrant expression of mucin core proteins and o-linked glycans associated with progression of pancreatic cancer. Clin Cancer Res (2013) 1.28
PUMA and BIM are required for oncogene inactivation-induced apoptosis. Sci Signal (2013) 1.28
Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis. J Neurosci (2003) 1.28
Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. J Control Release (2010) 1.28
Surface plasmon resonance imaging using a high numerical aperture microscope objective. Anal Chem (2007) 1.28
Nitrated {alpha}-synuclein-induced alterations in microglial immunity are regulated by CD4+ T cell subsets. J Immunol (2009) 1.27
Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease. J Neurosci (2009) 1.27
CD8+ cell depletion accelerates HIV-1 immunopathology in humanized mice. J Immunol (2010) 1.27
MicroRNA-21 dysregulates the expression of MEF2C in neurons in monkey and human SIV/HIV neurological disease. Cell Death Dis (2010) 1.26
CNS expression of anti-inflammatory cytokine interleukin-4 attenuates Alzheimer's disease-like pathogenesis in APP+PS1 bigenic mice. FASEB J (2010) 1.25
Regulation of nucleocytoplasmic trafficking of transcription factor OREBP/TonEBP/NFAT5. J Biol Chem (2006) 1.24
Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice. J Infect Dis (2012) 1.23
Hydrogen sulfide inhibits myocardial injury induced by homocysteine in rats. Amino Acids (2007) 1.23
Generation of cytotoxic T cells against virus-infected human brain macrophages in a murine model of HIV-1 encephalitis. J Immunol (2002) 1.23
Loss of neuronal integrity during progressive HIV-1 infection of humanized mice. J Neurosci (2011) 1.22
Regulation of tissue inhibitor of metalloproteinase-1 by astrocytes: links to HIV-1 dementia. Glia (2003) 1.22
Inflammation and adaptive immunity in Parkinson's disease. Cold Spring Harb Perspect Med (2012) 1.22
An ultra-high density bin-map for rapid QTL mapping for tassel and ear architecture in a large F₂ maize population. BMC Genomics (2014) 1.22
CCL2 accelerates microglia-mediated Abeta oligomer formation and progression of neurocognitive dysfunction. PLoS One (2009) 1.21
The atypical homeodomain transcription factor Mohawk controls tendon morphogenesis. Mol Cell Biol (2010) 1.21
Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections. Nanomedicine (2013) 1.21
Mining the biodiversity of plants: a revolution in the making. Science (2012) 1.21
Innate and adaptive immunity for the pathobiology of Parkinson's disease. Antioxid Redox Signal (2009) 1.20
Resolving the composition of protein complexes using a MALDI LTQ Orbitrap. J Am Soc Mass Spectrom (2009) 1.20
Vitamin D status and its associations with disease activity and severity in African Americans with recent-onset rheumatoid arthritis. J Rheumatol (2009) 1.19
Automated diagnoses of attention deficit hyperactive disorder using magnetic resonance imaging. Front Syst Neurosci (2012) 1.18